Pictet & Cie Europe SA continued to hold its position in VCA Inc. (NASDAQ:WOOF) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,500 shares of the company’s stock at the end of the first quarter. Pictet & Cie Europe SA’s holdings in VCA were worth $686,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Marshall Wace LLP boosted its stake in shares of VCA by 558.6% in the fourth quarter. Marshall Wace LLP now owns 1,241,291 shares of the company’s stock valued at $85,214,000 after buying an additional 1,052,831 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of VCA by 227.7% in the first quarter. JPMorgan Chase & Co. now owns 1,206,693 shares of the company’s stock worth $110,412,000 after buying an additional 838,452 shares during the period. Congress Asset Management Co. MA bought a new stake in shares of VCA during the fourth quarter worth approximately $52,493,000. Columbia Wanger Asset Management LLC boosted its stake in shares of VCA by 356.2% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 893,802 shares of the company’s stock worth $61,360,000 after buying an additional 697,862 shares during the period. Finally, Norges Bank bought a new stake in shares of VCA during the fourth quarter worth approximately $39,039,000. 73.93% of the stock is owned by institutional investors and hedge funds.
VCA Inc. (WOOF) traded down 0.17% on Tuesday, reaching $92.44. The company’s stock had a trading volume of 171,878 shares. VCA Inc. has a 12 month low of $59.51 and a 12 month high of $92.87. The firm has a market cap of $7.51 billion, a price-to-earnings ratio of 35.42 and a beta of 0.99. The firm has a 50 day moving average of $92.07 and a 200 day moving average of $87.05.
VCA (NASDAQ:WOOF) last released its earnings results on Thursday, April 27th. The company reported $0.73 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.76 by $0.03. The company had revenue of $678.25 million for the quarter, compared to analysts’ expectations of $679.92 million. VCA had a net margin of 8.13% and a return on equity of 15.61%. Analysts anticipate that VCA Inc. will post $3.10 earnings per share for the current year.
Several equities analysts recently issued reports on the company. Zacks Investment Research lowered VCA from a “hold” rating to a “sell” rating in a research report on Tuesday, May 2nd. Jefferies Group LLC reaffirmed a “hold” rating and set a $93.00 price target on shares of VCA in a research report on Friday, March 17th. Finally, BidaskClub upgraded VCA from a “hold” rating to a “buy” rating in a research note on Saturday. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. VCA presently has a consensus rating of “Hold” and a consensus target price of $86.60.
VCA Company Profile
VCA Inc is an animal healthcare company operating in the United States and Canada. The Company operates through five segments: animal hospitals (Animal Hospital), veterinary diagnostic laboratories (Laboratory), veterinary medical technology (Medical Technology), Vetstreet and Camp Bow Wow Franchising, Inc (Camp Bow Wow).
Receive News & Ratings for VCA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VCA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.